$NTRA

Sheena Jonathan sold $837K of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $265.68 ($262.72–$268.39, $0.84M total) across 6 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 16, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor for patterns in insider activity, but this specific disclosure lacks new fundamentals and is unlikely to drive a durable repricing by itself.

02

Market read

A disclosed insider sale by a director under a 10b5-1 plan, with no accompanying company-specific news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it quantify total insider ownership changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-07-15, covering sales dated 2026-07-13.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reported by a director and executed as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about 3,150 shares in an open-market sale totaling $836,898.26 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, contracts, or regulatory developments.

Market effects

Minimal. No sector-wide read-across is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may reflect scheduled liquidity needs rather than bearish expectations, so any negative tape reaction could be overdone.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Sheena Jonathan

    Director who sold shares totaling $836,898.26 across six trades on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.